Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Chronic Cytopenia in CTLA4 Haploinsufficiency
NCT03733067Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in CTLA4 haploinsufficiency (CHAI), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Nov 2023; status: withdrawn.
02
Drugs
abatacept
03
Conditions
CTLA4 haploinsufficiency (CHAI)
Beyond the preview
Go deeper on NCT03733067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733067.